Literature DB >> 15326292

Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Aymeric de Parseval1, Udayan Chatterji, Peiqing Sun, John H Elder.   

Abstract

The major surface glycoprotein of feline immunodeficiency virus (FIV) specifically binds to a 43-kDa glycoprotein expressed on the surface of a subset of T cells in peripheral blood mononuclear cells and IL-2-dependent T cell lines. Binding to this molecule, in conjunction with CXC chemokine receptor (CXCR) 4, is required for productive infection of these cells by primary isolates of FIV. Here, we demonstrate that the 43-kDa molecule is CD134, a receptor for FIV recently identified independently [Shimojima, M., et al. (2004) Science 303, 1192-1195]. Furthermore, we show that CD134 is specifically up-regulated on CD4+ T cells that have been activated by treatment with IL-2 and Con A. CD8+ T cells remained negative for CD134 expression regardless of the activation state. Binding of the FIV major surface glycoprotein on activated CD4+ T cells was observed through direct interaction with CD134 whereas, on activated CD8+ T cells, the binding was CD134-independent and mediated by CXCR4 and, to a lesser extent, heparan sulfate proteoglycans. However, this CD134-independent interaction was not sufficient to render CD8+ T cells permissive to FIV infection, as FIV replicated primarily in activated CD4+ T cells and not in cells negative for CD134 expression. Altogether, our results substantiate that CD134 acts as a primary binding receptor for FIV and explain the specific targeting and depletion of the CD4+ T cell population observed during the course of infection independent of the use of CD4 as a binding receptor/coreceptor. Copyright 2004 The National Academy of Sciencs of the USA

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326292      PMCID: PMC516514          DOI: 10.1073/pnas.0404006101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN.

Authors:  Aymeric de Parseval; Stephen V Su; John H Elder; Benhur Lee
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells.

Authors:  D L Lerner; J H Elder
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors.

Authors:  J C Johnston; M Gasmi; L E Lim; J H Elder; J K Yee; D J Jolly; K P Campbell; B L Davidson; S L Sauter
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37.

Authors:  E Wu; J Fernandez; S K Fleck; S Huang; G R Nemerow
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

6.  Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Authors:  C W Hendrix; C Flexner; R T MacFarland; C Giandomenico; E J Fuchs; E Redpath; G Bridger; G W Henson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.

Authors:  A C Saphire; M D Bobardt; Z Zhang; G David; P A Gallay
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators.

Authors:  Udayan Chatterji; Aymeric de Parseval; John H Elder
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Use of CD134 as a primary receptor by the feline immunodeficiency virus.

Authors:  Masayuki Shimojima; Takayuki Miyazawa; Yasuhiro Ikeda; Elizabeth L McMonagle; Hayley Haining; Hiroomi Akashi; Yasuhiro Takeuchi; Margaret J Hosie; Brian J Willett
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

Review 10.  The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement.

Authors:  Andrew D Weinberg; Dean E Evans; Colin Thalhofer; Tom Shi; Rodney A Prell
Journal:  J Leukoc Biol       Date:  2004-03-02       Impact factor: 4.962

View more
  54 in total

1.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

3.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

Review 4.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

5.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

Review 6.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

7.  Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein.

Authors:  Qiong-Ying Hu; Elizabeth Fink; Yang Hong; Cathy Wang; Chris K Grant; John H Elder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

8.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

9.  Expression of CD134 and CXCR4 mRNA in term placentas from FIV-infected and control cats.

Authors:  Veronica L Scott; Shane C Burgess; Leslie A Shack; Nikki N Lockett; Karen S Coats
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.

Authors:  Sean P Troth; Alan D Dean; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.